Company / Return on Equity (ROE)
Entrada Therapeutics, Inc. Return on Equity (ROE) History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
15.3%
FY2025
5-year range
-44.5% / 15.3%
FY2023-FY2025
Trend
+654.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Return on Equity (ROE) changed +655% YoY in FY2025, a notable deviation from the 2-year average annual change of +374%.
Based on SEC 10-K filings.
15.3% in FY2025.
Improved from -44.5% to 15.3% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, return on equity (roe) increased 654.7% year-over-year.
Company context
Key Data Points
- Altman Z-Score -2.03 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | 15.3% | +654.7% |
| FY2024 | -2.8% | +93.8% |
| FY2023 | -44.5% | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026